Karyopharm files Chapter 11, with Ayrmid as lead bidder in a court-supervised sale
- Karyopharm Therapeutics filed for Chapter 11 in the Southern District of Texas, announcing the move on Nov. 2 in place of its expected third-quarter earnings.
- Ayrmid, a U.K. biotech and parent of Gamida Cell, is the lead bidder in a court-supervised sale; rivals may still bid. Its offer price is undisclosed, and closing is targeted for Q1 2027.
- Karyopharm has commitments for up to $55 million in debtor-in-possession financing from existing secured lenders, subject to court approval.
- The company says it will operate normally and keep advancing its myeloma and myelofibrosis programs; no layoffs are tied to the announcement.
💡 Points Based on public reports
A lead bidder with an undisclosed price and up to $55M of DIP money looks like a floor-setting bid, not a rescue. Ayrmid, parent of Gamida Cell, gets a commercial XPO1 inhibitor with myeloma and myelofibrosis optionality; the open questions are whether trial funding lasts until a Q1 2027 close and whether rival bids lift the price.
Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft ↗